- Home
- QTTB vs SERA Comparison
QTTB vs SERA Comparison
Compare QTTB & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QTTB | SERA |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.0M | 79.5M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | QTTB | SERA |
|---|---|---|
| Price | $5.56 | $2.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | ★ 306.7K | 18.1K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 136.78 | 32.32 |
| EPS | ★ 2.42 | N/A |
| Revenue | ★ $53,737,000.00 | $81,000.00 |
| Revenue This Year | N/A | $554.81 |
| Revenue Next Year | N/A | $517.27 |
| P/E Ratio | $2.37 | ★ N/A |
| Revenue Growth | N/A | ★ 5.19 |
| 52 Week Low | $1.40 | $1.37 |
| 52 Week High | $8.05 | $4.09 |
Technical Indicators
Market Signals| Indicator | QTTB | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 46.00 | 42.48 |
| Support Level | $5.51 | $1.91 |
| Resistance Level | $7.69 | $2.41 |
| Average True Range (ATR) | 0.64 | 0.16 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 32.93 | 15.91 |
Price Performance
Historical ComparisonAbout QTTB Q32 Bio Inc.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.